Genfit was hit hard last year when it abandoned a phase 3 programme for elafibranor in non-alcoholic steatohepatitis (NASH), but pledged to press on with the drug in other indications – and
Patients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb's immunotherapy Opdivo with Ipsen's targeted drug Cabometyx, ahead o
Ipsen's new chief executive David Loew pledged to ramp up spending on the company's pipeline when he took the helm last year, and a flurry of licensing deals in the last few weeks shows tha
French drugmaker Ipsen has made another foray into the Parkinson's disease category, licensing rights to an oral dopamine D3 receptor antagonist from Sweden's IRLAB for $28 million upfront.
Exelixis has suffered a blow to its efforts to expand the use of Cabometyx into additional indications after reporting mixed results in a phase 3 trial in liver cancer.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl